160 related articles for article (PubMed ID: 15473023)
21. [Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Doi T; Ohtsu A
Nihon Rinsho; 2003 Sep; 61 Suppl 7():368-73. PubMed ID: 14574915
[No Abstract] [Full Text] [Related]
22. New treatments for colorectal cancer.
FDA Consum; 2004; 38(3):17. PubMed ID: 15218840
[No Abstract] [Full Text] [Related]
23. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.
Tappenden P; Jones R; Paisley S; Carroll C
Eur J Cancer; 2007 Nov; 43(17):2487-94. PubMed ID: 17910914
[TBL] [Abstract][Full Text] [Related]
24. When more is worse in clinical research and clinical practice.
Tassinari D; Tombesi P; Sartori S
Am J Clin Oncol; 2010 Aug; 33(4):424. PubMed ID: 20689366
[No Abstract] [Full Text] [Related]
25. [A case of rectal cancer with lung metastases responding to cetuximab].
Kawai H; Uetake H; Kobayashi H; Enomoto M; Higuchi T; Yasuno M; Iida S; Ishikawa T; Sugihara K
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2152-4. PubMed ID: 20037353
[TBL] [Abstract][Full Text] [Related]
26. [Cetuximab].
Takiuchi H
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1192-5. PubMed ID: 17687200
[TBL] [Abstract][Full Text] [Related]
27. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.
Mahtani RL; Macdonald JS
Oncologist; 2008 Jan; 13(1):39-50. PubMed ID: 18245011
[TBL] [Abstract][Full Text] [Related]
28. Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials.
Owzar K
J Clin Oncol; 2008 Mar; 26(9):1400-1. PubMed ID: 18349389
[No Abstract] [Full Text] [Related]
29. Two new drugs for colon cancer.
Med Lett Drugs Ther; 2004 Jun; 46(1184):46-8. PubMed ID: 15184808
[No Abstract] [Full Text] [Related]
30. [Pulmonary embolism during palliative chemotherapy including cetuximab for metastatic colorectal cancer].
Goto A; Suzuki K; Hasegawa Y; Sukawa Y; Fujii K; Nishimura S; Yonezawa K; Abe T; Shinomura Y
Gan To Kagaku Ryoho; 2010 Jan; 37(1):169-71. PubMed ID: 20087056
[TBL] [Abstract][Full Text] [Related]
31. [Palliative chemotherapy and radiotherapy for metastatic colorectal cancer].
Sørbye H; Braendengen M; Balteskard L
Tidsskr Nor Laegeforen; 2008 Jan; 128(2):194-7. PubMed ID: 18202732
[TBL] [Abstract][Full Text] [Related]
32. Progress in the development of novel treatments for colorectal cancer.
Hoff PM; Pazdur R
Oncology (Williston Park); 2004 May; 18(6):705-8. PubMed ID: 15214591
[TBL] [Abstract][Full Text] [Related]
33. Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report.
Berretta M; Martellotta F; Simonelli C; Di Benedetto F; De Ruvo N; Drigo A; Bearz A; Spina M; Zanet E; Berretta S; Tirelli U
J Chemother; 2007 Jun; 19(3):343-6. PubMed ID: 17594933
[TBL] [Abstract][Full Text] [Related]
34. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
36. Challenges and opportunities for use of cost-effectiveness analysis.
Yabroff KR; Schrag D
J Natl Cancer Inst; 2009 Sep; 101(17):1161-3. PubMed ID: 19666852
[No Abstract] [Full Text] [Related]
37. Erbitux trial flawed from the beginning, committee finds.
Randal J
J Natl Cancer Inst; 2002 Dec; 94(24):1824-5. PubMed ID: 12488469
[No Abstract] [Full Text] [Related]
38. [Improving longevity in advanced intestinal cancer].
Schmoll HJ
Krankenpfl J; 2005; 43(1-3):48. PubMed ID: 15912837
[No Abstract] [Full Text] [Related]
39. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
Saltz LB; Lenz HJ; Kindler HL; Hochster HS; Wadler S; Hoff PM; Kemeny NE; Hollywood EM; Gonen M; Quinones M; Morse M; Chen HX
J Clin Oncol; 2007 Oct; 25(29):4557-61. PubMed ID: 17876013
[TBL] [Abstract][Full Text] [Related]
40. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
